Pigs and pig cells having an inactivated α...

Details Pigs and pig cells having an inactivated α... Pigs and pig cells having an inactivated α...

2005-02-01

2005-02-01

Chen, Shin-Lin (Department: 1632)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S320100, C435S455000, C536S023100, C536S023500

Reexamination Certificate

active

06849448

ABSTRACT:
Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed are materials and methods for removing or neutralizing such antibodies. Also disclosed are materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are formed as the result of activity by the enzyme α-1,3 galactosyltransferase. The porcine gene encoding α-1,3 galactosyltransferase is disclosed, as are materials and methods for inactivating (“knocking out”) the α-1,3 galactosyltransferase gene in mammalian cells and embryos. Included are nucleic acid constructs useful for inactivating the α-1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture.

REFERENCES:
patent: 5527695 (1996-06-01), Hodges et al.
patent: 5821117 (1998-10-01), Sandrin et al.
patent: PL 7854 (1994-10-01), None
patent: 2011784 (1990-08-01), None
patent: 235805 (1987-09-01), None
patent: WO 8807548 (1988-10-01), None
patent: WO 9003432 (1990-04-01), None
patent: WO 9008188 (1990-07-01), None
patent: WO 9113985 (1991-09-01), None
patent: WO 9119796 (1991-12-01), None
patent: WO 9207581 (1992-05-01), None
patent: WO 9316729 (1993-09-01), None
patent: WO 9402616 (1994-02-01), None
patent: WO 9421799 (1994-09-01), None
Deonarain: Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents 8: 53-69.*
Verma et al.; Gene therapy-promises, problems and prospects, 1997, Nature, vol. 389: 239-242.*
Eck et al.; Gene-Based Therapy, 1996, Pharmacological Basis of Therapeutics: 77-101.*
Wu et.al. Methods of Gene Biotechnology, 1997, New Strategies for Gene Knockout: 339-365.*
Palmiter et al.; Mettallothionein—Human GH Fusion Genes Stimulate Growth of Mice, 1983, Science, vol. 222 809-814.*
Pursel et.al.; Expression and performance in transgenic pigs, 1990, J. Reprod. Fert. Suppl. 40: 235-245.*
Sigmund; Viewpoint: Are Studies in Genetically Altered Mice Out of Control?.2000, Arterioscler Thromb Vasc Biol. 20: 1425-1429.*
Skolnick et.al.; From genes to protein structure and function: novel applications of computational approaches in the genomic era, 2000, TIBTECH, vol. 18: 34-39.*
Rudinger: Characteristics of the amino acids as components of a peptide hormone sequence, 1976, Peptide Hormones : 1-7.*
Kaye: A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding, 1990, Proc. Natl. Acad. Sci., vol. 87: 6922-6926.*
Stanton et al., the N-myc Proto-oncogene: Developmental expression and in vivo site-directed mutagenesis, 1992, Brain Pathology, vol. 2, pp. 71-83.*
Strahan et al., GenEmbl Accession No. L36152, Jul. 1995.*
Strahan et al., Immunogenetics, vol. 41, p. 101-105, 1995.*
Ohgi et al., J. Biochem. vol 109, p. 776-785, 1991.*
Uri Galili, Immunology Today, vol. 14(10), p. 480-482, 1993.*
Louis-Marie Houdebine, Journal of Biotechnology 34, p. 269-287, 1994.*
R. F. Seamark, Reprod. Fertl. Dev., 6, p. 653-7, 1994.*
Gustafsson et al., Immunological Reviews, No. 141, p. 59-70, 1994.*
Sandrin et al., GenBank Accession No. L36535, Jan. 1995.*
Sandrin et al.,Proc. Natl. Acad. Sci. USA, 90:11391-11395 (1993).
Liu et al.,Int. J. Dev. Biol., 39:639-644 (1995).
Matsui et al.,Cell, 70:841-847 (1992).
Sandrin et al.,Immunological Reviews, 141:169-190 (1994).
Gustafsson et al.,Immunological Reviews, 141:59-70 (1994).
Galili,Immunology Today, 14:480-482 (1993).
Larsen et al,Proc. Natl. Acad. Sci. USA, 86:8227-8231 (1989).
Fletcher et al.,J. of Exp. Medicine, 174:837-845 (1991).
Samal et al.,Biochimica et Biophysica Acta, 1260:27-34 (1995).
Willson et al.,European J. of Biochem., 204:21-30 (1992).
Gough et al.Proc. Natl. Acad. Sci., 85:2623-2627 (1988).
Gearing et al.,Nucleic Acids Res., 16:9857 (1988).
Moreau et al.,Nature, 336:690-692 (1988).
Gearing et al.,Bio/Technology, 7:1157-1161 (1989).
Yamamori et al.,Science, 246:1412-1416 (1989).
Lowe et al.,DNA, 8:351-359 (1989).
Stahl et al.,J. Biol. Chem., 265:8833-8841 (1990).
Vaughan et al.,Transplantation, 58:879-882 (1994).
Latinne et al.,Immunological Reviews, 141:95-125 (1994).
Soares et al.,Transplantation, 57:1003-1009 (1994).
Soares et al.,Transplantation, 56:1427-1433 (1993).
Gambiez et al.,Transplantation, 54:577-583 (1992).
Oriol et al.,Transplant Internations, 7:405-413 (1994).
Hale et al.,Blood, 62:873-882 (1983).
Dabkowski et al.,Transplant. Proc., 25:2921 (1993).
Paulson et al.,J. Biol. Chem., 264:17615-17618 (1989).
Joziasse et al.,J. Biol. Chem., 267:5534-5541 (1992).
Thomas et al.,Cell, 51:503-512 (1987).
Capecchi,Trends in Genetics, 5:70-76 (1989).
Jung et al.,Science, 259:984-987 (1993).
Joziasse et al.,J. Biol. Chem., 264:14290-14297 (1989).
Brinster et al.,Proc. Natl. Acad. Sci. USA, 86:7087-7091 (1989).
Rathjen et al.,Cell, 62:1105-1114 (1990).
Galili,The Lancet, pp. 358-360, Aug. 12, 1989.
Thall et al.,Autoimmunity, 10:81-87 (1991).
Good et al.,Transplant. Proc., 24:559-62 (1992).
Galili,Springer Sem. Immunopathol., 15:155-71 (1993).
Galili,Xeno, 2:84-87 (1994).
Resnick et al.,Nature, 359:550-551 (1992).
Capecchi, M.R., (ed.),Molecular Genetics of Early Drosophilia and Mouse Developmentpp. 39-44 (Cold Springs Harbor Lab. Press, 1989).
Jaenisch, R.,Science, 240:1468-1474 (1988).
Laus, et al.,Int. Archs Allergy Appl. Immun., 85:201-207 (1988).
Hendricks, S.P., et al.,J. Bio. Chem., 265:17621-17626 (1990).
Platt, J.L., et al.,Transplantation, 50:817-822 (1990).
Galili, U., et al.,J. Bio. Chem., 263:17755-17762 (1988).
Smith, D.F., et al.,J. Fed. Am. Soc. Exp. Biol., 4:A1979 (1990).
Hindsgaul, D., et al.,J. Bio. Chem., 266:17858-17862 (1991).
Cooper, D.K.C., et al.,Transplantation Proceedings, 24:566-571 (1992).
Cooper, D.K.C., et al.,Xeno-transplantation, pp. 47-49, 170-178, 312-321, 429-438, 500-510, (Springer-Verlag Berlin Heidelberg, 1991).
Platt, J.L., et al.,Immunology, 3:735-739 (1991).
Miyagawa, S., et al.,Transplantation Proceedings, 21:520-521 (1989).
Platt, J.L., et al.,Immunology Today, 11:450-456 (1990).
Ware, C.B., et al.,Biology of Reproduction(Supplement), 38:129 (1988).
Piedrahita, J.A.,Theriogenology, 29:286 (1988).
Thompson, S., et al.,Cell, 56:313-321 (1989).
Zimmer, A., et al.,Nature, 338:150-153 (1989).
Capecchi, M.R.,Science, 244:1288-1292 (1989).
Kidd, V.J., et al.,J. Cell Biochem.(Suppl.), p. 200 (1988).
Abstracts from the 2nd International Congress on Xenotransplantation, Cambridge, England, Sep. 26-29, 1993.
Abstracts from 11th Meeting of Transplant Society of Australia and New Zealand, Australia, May 5-7, 1993.
Fournier et al., “A Human Naturally Occurring Antibody, Anti-Gal, Recognises Epitopes in Pig Kidney, Heart and Liver and is Cytotoxic to Endothelial Cells in the Presence of Rabbit Complement,” Abstract, #113, p. 142, Second International Congress on Xenotransplantation held in Cambridge, England Sep. 26-29, 1993.
Dabkowski et al., “Isolation of a cDNA Clone Encoding the Pig α1.3 Galactosyltransferase,” Transplantation Proceedings 26(3):1335, 1994.
Cooper et al., “Genetically engineered pigs,” The Lancet 342:682-683, 1993.
Hogan et al., “Getting nearer the mark,” Nature 336:304-305, 1988.
Mansour et al., “Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes,” Nature 336:348-352, 1988.
O'Gorman et al., “Recombinase-Mediated Gene Activation and Site-Specific Integration in Mammalian Cells,” Science 251:1351-1355, 1991.
Capecchi, “Lapping the cellular telephone,” Nature 344:10, 1990.
Alberts et al., (eds.),Molecular Biology of the Cell, Garland Publishing, Inc.: New York and London, 1989, pp. 194, 195, 894-896, 900, 901.
Sandrin et al., “Studies on Human Naturally Occurring Antibodies to Pig Xenografts,” Transplantation Proceedings, 25(5):2917-2918 1

Affiliated with

Also associated with

Rating

Pigs and pig cells having an inactivated α... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pigs and pig cells having an inactivated α..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pigs and pig cells having an inactivated α... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3473290